Johnson & Johnson (J&J)
Diversified healthcare company with pharma-plus-medtech footprint. Represented by John Reed at Session II.
Disease-Area Strongholds
Fifteen disease-area strongholds across oncology, immunology, and neuroscience — some 20 years old, some aspirational. Long horizons; deep patient and HCP fluency translated back into science.
Key Programs
Oncology
- Multiple myeloma: Velcade, Darzalex, Carvykti, Tecvayli, Talvey
- Prostate: Zytiga, Erleada, pasritamig (KLK2×CD3), RIPTAC
- Bladder: Inlexzo, erdafitinib-eluting device
Immunology
- Icotrokinra (Icotide) — oral IL-23R blocker
Neuroscience
Pharma + Medtech Advantage
Uniquely positioned to combine drug payloads with device delivery — intravesical drug-eluting devices for bladder cancer are design space others structurally can’t access.
Comments